Cinzia Rinaldo

List of Publications by Year
in descending order

38 papers	2,051 citations	236925 25 h-index	315739 38 g-index
41 all docs	41 docs citations	41 times ranked	2883 citing authors

#	Article	IF	Citations
1	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene, 2006, 25, 304-309.	5.9	188
2	MDM2-Regulated Degradation of HIPK2 Prevents p53Ser46 Phosphorylation and DNA Damage-Induced Apoptosis. Molecular Cell, 2007, 25, 739-750.	9.7	161
3	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death and Differentiation, 2012, 19, 768-778.	11.2	157
4	Roles for <i>Caenorhabditis elegans rad-51</i> in Meiosis and in Resistance to Ionizing Radiation During Development. Genetics, 2002, 160, 471-479.	2.9	119
5	HIPK2: a multitalented partner for transcription factors in DNA damage response and developmentThis paper is one of a selection of papers published in this Special Issue, entitled 28th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology, 2007, 85, 411-418.	2.0	115
6	Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Experimental Cell Research, 2004, 293, 311-320.	2.6	99
7	Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis. Molecular and Cellular Biology, 2006, 26, 4746-4757.	2.3	93
8	Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. Journal of Molecular Medicine, 2009, 87, 1221-1239.	3.9	88
9	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation, 2007, 117, 693-702.	8.2	88
10	Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. Journal of Experimental and Clinical Cancer Research, 2012, 31, 63.	8.6	81
11	MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO Journal, 2009, 28, 1926-1939.	7.8	75
12	High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death and Differentiation, 2006, 13, 1554-1563.	11.2	65
13	HIPKs: Jack of all trades in basic nuclear activities. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2124-2129.	4.1	58
14	HIPK2 Controls Cytokinesis and Prevents Tetraploidization by Phosphorylating Histone H2B at the Midbody. Molecular Cell, 2012, 47, 87-98.	9.7	58
15	HIPK2 phosphorylates Î”Np63Î± and promotes its degradation in response to DNA damage. Oncogene, 2011, 30, 4802-4813.	5.9	57
16	ESCRT-III is necessary for the integrity of the nuclear envelope in micronuclei but is aberrant at ruptured micronuclear envelopes generating damage. Oncogenesis, 2019, 8, 29.	4.9	57
17	The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas. PLoS ONE, 2011, 6, e20665.	2.5	54
18	HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA. Cancer Research, 2009, 69, 6241-6248.	0.9	49

#	Article	IF	Citations
19	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Oncotarget, 2015, 6, 32089-32103.	1.8	36
20	<i>Galâ€3</i> is stimulated by gainâ€ofâ€function <i>p53</i> mutations and modulates chemoresistance in anaplastic thyroid carcinomas. Journal of Pathology, 2009, 218, 66-75.	4.5	33
21	HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Proliferation, 2009, 42, 373-384.	5.3	33
22	HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission. Cells, 2019, 8, 684.	4.1	31
23	MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. Molecular Cancer Research, 2011, 9, 67-77.	3.4	30
24	HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget, 2015, 6, 10320-10334.	1.8	30
25	CDKL5 localizes at the centrosome and midbody and is required for faithful cell division. Scientific Reports, 2017, 7, 6228.	3.3	27
26	Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes. Oncotarget, 2015, 6, 17342-17353.	1.8	27
27	p53 mitotic centrosome localization preserves centrosome integrity and works as sensor for the mitotic surveillance pathway. Cell Death and Disease, 2019, 10, 850.	6.3	26
28	The Caenorhabditis elegansRAD51 homolog is transcribed into two alternative mRNAs potentially encoding proteins of different sizes. Molecular Genetics and Genomics, 1998, 260, 289-294.	2.4	24
29	Spastin recovery in hereditary spastic paraplegia by preventing neddylation-dependent degradation. Life Science Alliance, 2020, 3, e202000799.	2.8	19
30	HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis. Oncogene, 2018, 37, 3562-3574.	5.9	15
31	An Alternative Splice Variant of HIPK2 with Intron Retention Contributes to Cytokinesis. Cells, 2020, 9, 484.	4.1	13
32	HIPK2 sustains apoptotic response by phosphorylating Che-1/AATF and promoting its degradation. Cell Death and Disease, 2014, 5, e1414-e1414.	6.3	11
33	Homeodomain-interacting Protein Kinase-2 Stabilizes p27kip1 by Its Phosphorylation at Serine 10 and Contributes to Cell Motility. Journal of Biological Chemistry, 2011, 286, 29005-29013.	3.4	9
34	<i>Hmga1</i>null mouse embryonic fibroblasts display downregulation of spindle assembly checkpoint gene expression associated to nuclear and karyotypic abnormalities. Cell Cycle, 2016, 15, 812-818.	2.6	9
35	HIPK2 Is Required for Midbody Remnant Removal Through Autophagy-Mediated Degradation. Frontiers in Cell and Developmental Biology, 2020, 8, 572094.	3.7	7
36	Effects of Y361â€autoâ€phosphorylation on structural plasticity of the HIPK2 kinase domain. Protein Science, 2018, 27, 725-737.	7.6	4

#	Article	IF	Citations
37	Extrachromosomal Histone H2B Contributes to the Formation of the Abscission Site for Cell Division. Cells, 2019, 8, 1391.	4.1	4
38	Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,. Blood, 2011, 118, 3581-3581.	1.4	0